

A randomized controlled trial into the effects of **neurofeedback**, methylphenidate, and physical activity on EEG power spectra in children with ADHD.

Authors: [Janssen TW](#); Department of Clinical Neuropsychology, VU University Amsterdam, Amsterdam, The Netherlands.
[Bink M](#); Department of Clinical Neuropsychology, VU University Amsterdam, Amsterdam, The Netherlands.
[Geladé K](#); Department of Clinical Neuropsychology, VU University Amsterdam, Amsterdam, The Netherlands.; Yulius Academy, Barendrecht, The Netherlands.
[van Mourik R](#); Royal Dutch Kentalis, Utrecht, The Netherlands.
[Maras A](#); Yulius Academy, Barendrecht, The Netherlands.
[Oosterlaan J](#); Department of Clinical Neuropsychology, VU University Amsterdam, Amsterdam, The Netherlands.

Source: [Journal Of Child Psychology And Psychiatry, And Allied Disciplines \[J Child Psychol Psychiatry\]](#) 2016 May; Vol. 57 (5), pp. 633-44. *Date of Electronic Publication:* 2016 Jan 08.

Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Language: English

Journal Info: *Publisher:* [Blackwell Publishers](#) *Country of Publication:* England *NLM ID:* 0375361 *Publication Model:* Print-Electronic *Cited Medium:* Internet *ISSN:* 1469-7610 (Electronic) *Linking ISSN:* [00219630](#) *NLM ISO Abbreviation:* J Child Psychol Psychiatry *Subsets:* MEDLINE

Imprint Name(s): *Publication:* 2002- : Oxford : Blackwell Publishers
Original Publication: Oxford ; New York : Pergamon Press

MeSH Terms: [Outcome Assessment \(Health Care\)*](#)
[Attention Deficit Disorder with Hyperactivity/*physiopathology](#)
[Attention Deficit Disorder with Hyperactivity/*therapy](#)
[Brain Waves/*physiology](#)
[Central Nervous System Stimulants/*pharmacology](#)
[Exercise Therapy/*methods](#)
[Methylphenidate/*pharmacology](#)
[Neurofeedback/*physiology](#)
[Adolescent ; Brain Waves/drug effects ; Central Nervous System Stimulants/administration & dosage ; Child ; Double-Blind Method ; Female; Humans ; Male ; Methylphenidate/administration & dosage](#)

Abstract: **Background:** The clinical and neurophysiological effects of **neurofeedback**(NF) as treatment for children with ADHD are still unclear. This randomized controlled trial (RCT) examined electroencephalogram (EEG) power spectra before and after NF compared to methylphenidate (MPH) treatment and physical activity (PA) - as semi-active control group - during resting and active (effortful) task conditions to determine whether NF can induce sustained alterations in brain function.


Methods: Using a multicentre three-way parallel group RCT design, 112 children with a DSM-IV diagnosis of ADHD, aged between 7 and 13 years, were initially included. NF training consisted of 30 sessions of theta/beta training at Cz over a 10-week period. PA training was a semi-active control group, matched in frequency and duration. Methylphenidate was titrated using a double-blind placebo controlled procedure in 6 weeks, followed by a stable dose for 4 weeks. EEG power spectra measures during eyes open (EO), eyes closed (EC) and task (effortful) conditions were available for 81 children at pre- and postintervention (n = 29 NF, n = 25 MPH, n = 27 PA).

Clinical Trials Registration: Train Your Brain? Exercise and **Neurofeedback** Intervention for ADHD, <https://clinicaltrials.gov/show/NCT01363544>, Ref. No. NCT01363544.

Results: Both NF and MPH resulted in comparable reductions in theta power from pre- to postintervention during the EO condition compared to PA ($\eta^2(2) = .08$ and $.12$). For NF, greater reductions in theta were related to greater reductions in ADHD symptoms. During the task condition, only MPH showed reductions in theta and alpha power compared to PA ($\eta^2(2) = .10$ and $.12$).

Conclusions: This study provides evidence for specific neurophysiological effects after theta/beta NF and MPH treatment in children with ADHD. However, for NF these effects did not generalize to an active task condition, potentially explaining reduced behavioural effects of NF in the classroom.

(© 2016 Association for Child and Adolescent Mental Health.)



Contributed Indexing: *Keywords:* ADHD; EEG; RCT; methylphenidate; **neurofeedback**; physical activity

Molecular Sequence: ClinicalTrials.gov NCT01363544

Substance 0 (Central Nervous System Stimulants)

Nomenclature: 207ZZ9QZ49 (Methylphenidate)

Entry Date(s): *Date Created:* 20160419 *Date Completed:* 20170117 *Latest Revision:* 20170117

Update Code: 20170119

DOI: 10.1111/jcpp.12517

PMID: 26748531

Database: MEDLINE

A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD

Tieme W. P. Janssen,¹ Marleen Bink,¹ Katleen Geladé,^{1,2} Rosa van Mourik,³
Athanasios Maras,² and Jaap Oosterlaan¹

¹Department of Clinical Neuropsychology, VU University Amsterdam, Amsterdam; ²Yulius Academy, Barendrecht; ³Royal Dutch Kentalis, Utrecht, The Netherlands

Background: The clinical and neurophysiological effects of neurofeedback (NF) as treatment for children with ADHD are still unclear. This randomized controlled trial (RCT) examined electroencephalogram (EEG) power spectra before and after NF compared to methylphenidate (MPH) treatment and physical activity (PA) – as semi-active control group – during resting and active (effortful) task conditions to determine whether NF can induce sustained alterations in brain function. **Methods:** Using a multicentre three-way parallel group RCT design, 112 children with a DSM-IV diagnosis of ADHD, aged between 7 and 13 years, were initially included. NF training consisted of 30 sessions of theta/beta training at Cz over a 10-week period. PA training was a semi-active control group, matched in frequency and duration. Methylphenidate was titrated using a double-blind placebo controlled procedure in 6 weeks, followed by a stable dose for 4 weeks. EEG power spectra measures during eyes open (EO), eyes closed (EC) and task (effortful) conditions were available for 81 children at pre- and postintervention ($n = 29$ NF, $n = 25$ MPH, $n = 27$ PA). Clinical trials registration: Train Your Brain? Exercise and Neurofeedback Intervention for ADHD, <https://clinicaltrials.gov/show/NCT01363544>, Ref. No. NCT01363544. **Results:** Both NF and MPH resulted in comparable reductions in theta power from pre- to postintervention during the EO condition compared to PA ($\eta_p^2 = .08$ and $.12$). For NF, greater reductions in theta were related to greater reductions in ADHD symptoms. During the task condition, only MPH showed reductions in theta and alpha power compared to PA ($\eta_p^2 = .10$ and $.12$). **Conclusions:** This study provides evidence for specific neurophysiological effects after theta/beta NF and MPH treatment in children with ADHD. However, for NF these effects did not generalize to an active task condition, potentially explaining reduced behavioural effects of NF in the classroom. **Keywords:** ADHD; neurofeedback; methylphenidate; physical activity; EEG; RCT.

Introduction

ADHD is a common neuropsychiatric disorder in children, affecting 6–7% of the population (Willcutt, 2012), which broadly impacts academic and social functioning (Biederman, 2005; Coghill et al., 2008). Although stimulant medication is effective in short-term symptom reduction (Faraone & Buitelaar, 2010), approximately 30% do not respond favourably (Spencer et al., 1996) or experience adverse effects (Graham & Coghill, 2008). These disadvantages have spurred the development of non-pharmacological treatments for ADHD such as neurofeedback (NF). Despite that NF aims to target brain function directly, electroencephalographic (EEG) treatment effects have received little consideration.

Neurofeedback is a behavioural therapy that is based on operant conditioning of specific brain states by providing real-time feedback of EEG signals. The feedback signal of interest in ADHD has been derived (Lubar, 1991) from studies that show increased slow wave activity (theta: 4–8 Hz) and decreased fast wave activity (beta: 13–21 Hz) in the spontaneous EEG of children with ADHD (Snyder &

Hall, 2006). Originally, these findings have been interpreted as indices of hypo-arousal that may play a causative role in ADHD symptomatology, consistent with the cognitive-energetic model of ADHD (Sergeant, 2000; Zentall & Zentall, 1983). Accordingly, decreasing the ratio of theta/beta and/or increasing sensorimotor rhythm (SMR) with NF was hypothesized to ameliorate symptoms of ADHD. More recent studies, however, question the validity of theta/beta ratio as clinical biomarker of ADHD (Arns, Conners, & Kraemer, 2013; Loo et al., 2013; Snyder, Rugino, Hornig, & Stein, 2015), and several research groups increasingly embrace the possibility that NF does not address the neural dysfunction, but rather learns compensatory mechanisms (Arns, Heinrich, & Strehl, 2014; Gevensleben, Rothenberger, Moll, & Heinrich, 2012), which may involve CNS specific effects as well.

The efficacy of NF as treatment for ADHD is still debated. Although most researchers agree that treatment studies should be randomized and controlled, most of the discussion revolves around which kind of control group is appropriate to control for non-specific treatment effects (Loo & Makeig, 2012). Not surprisingly, systematic reviews differ in conclusions from ‘no evidence for effectiveness using

Conflict of interest statement: No conflicts declared.

blinded assessments' (Sonuga-Barke et al., 2013) to 'neurofeedback is efficacious and specific' (Arns, de Ridder, & Strehl, 2009).

Neural mechanisms that could underlie behavioural effects of theta/beta NF are yet unknown. However, pre- and posttreatment measurements of the spectral content of EEG can indicate if NF induces sustained alterations in brain function. Few randomized controlled trial (RCT) studies have actually examined EEG changes (Gevensleben et al., 2009; Ogrim & Hestad, 2013). The study by Gevensleben et al. (2009) is the only RCT that found a reduction in theta activity at midline scalp sites for the NF group compared to the control group. No changes were demonstrated for beta activity or theta/beta ratio. Furthermore, the theta reduction was only found for the theta/beta and SCP training blocks combined, but not separately, indicating that this effect was not protocol-specific. Clinically, a more relevant finding was that higher theta at baseline was predictive of a greater decrease in ADHD symptoms in the theta/beta NF group. Another, uncontrolled study, found comparable results of reductions in theta from pre- to posttreatment (Monastra, Monastra, & George, 2002). Two other studies failed to show any changes in power spectra (Kropotov et al., 2007; Ogrim & Hestad, 2013). Overall, preliminary evidence suggests that NF may induce chronic alterations in brain function; however, the specificity of these treatment effects remains unclear.

Methylphenidate (MPH) is the most widely prescribed psychostimulant for ADHD, and presumably acts by increasing activation in dopamine and norepinephrine fronto-striatal circuitry (Arnsten, 2006). Surprisingly, most studies on the effects of MPH on EEG power spectra are uncontrolled, with EEG recorded off and on medication. These studies mostly show decreases in theta activity (Clarke, Barry, Bond, McCarthy, & Selikowitz, 2002; Clarke et al., 2003; Song, Shin, Jon, & Ha, 2005; Swartwood et al., 1998) and/or increases in beta activity with MPH (Clarke, Barry, Bond, et al., 2002; Clarke et al., 2003; Song et al., 2005). Furthermore, clinical responders seem to be characterized by increased theta activity at baseline compared to nonresponders (Clarke, Barry, McCarthy, & Selikowitz, 2002; Ogrim et al., 2014). One double-blind placebo-controlled study demonstrated that MPH administration increased parietal alpha activity during the rest condition, and increased beta during a CPT, but had no effects on theta (Loo, Hopfer, Teale, & Reite, 2004). Overall, the literature indicates that MPH may reduce slow wave activity and increase fast wave activity; however, there is considerable variability in study design and outcomes, and lack of controlled studies.

Direct comparisons of NF and stimulant medication have produced inconsistent results, with studies showing comparable clinical effects (Duric,

Assmus, Gundersen, & Elgen, 2012; Meisel, Servera, Garcia-Banda, Cardo, & Moreno, 2013) or superior effects for medication (Ogrim & Hestad, 2013). Only the study of Ogrim and Hestad (2013) examined EEG power spectra as well, and found no changes in both the NF and medication groups.

Physical activity (PA) could be another treatment approach for ADHD that utilizes protective effects of exercise on brain functioning (Rommel, Halperin, Mill, Asherson, & Kuntsi, 2013). However, beneficial effects of chronic exercise in children with ADHD are preliminary and have yet to be established in RCTs (Halperin, Berwid, & O'Neill, 2014). In this study, PA was applied as a semiactive treatment condition to control for nonspecific treatment effects such as parental engagement and personal attention. Therefore, NF and PA training were matched on duration and intensity.

Few studies into EEG effects of theta/beta NF and MPH have been randomized and controlled, precluding more definitive evidence for treatment-related changes in power spectra. Furthermore, previous studies have assessed EEG effects with varying study designs, mostly using only an eyes open (EO) resting, eyes closed (EC) resting or task condition, while differential effects for treatments across these conditions may be more informative. Therefore, the aims of the current RCT were threefold: (a) to explore EEG effects in EC, EO and active task conditions, (b) to compare NF with optimally titrated MPH and (c) to compare NF with PA as semiactive control group. For the active task condition, we explored effects on the stop-signal task (SST) (Logan & Cowan, 1984), which is a widely used task to measure response inhibition deficits in ADHD (Alderson, Rapport, & Kofler, 2007; Lijffijt, Kenemans, Verbaten, & van Engeland, 2005) that are considered as one of the core problems in ADHD (Barkley, 1997; Sonuga-Barke, Bitsakou, & Thompson, 2010).

Methods

Participants

Eligible participants were Dutch-speaking children, aged 7–13 years, with a primary clinical DSM-IV-TR diagnosis of ADHD. Parent- and teacher ratings on the Disruptive Behaviour Disorders Rating Scale (DBDRS) (Pelham, Gnagy, Greenslade, & Milich, 1992) required at least one of the scores on the Inattention or Hyperactivity/Impulsivity scales to be above the 90th percentile for one of the informants, and one above the 70th percentile for the other informant. At study entry, all children were stimulant-free for at least 1 month. Exclusion criteria were neurological disorders and an estimated IQ below 80 on the abbreviated version of the Wechsler Intelligence Scale for Children (WISC-III; Wechsler, 1991), using subtests Vocabulary, Arithmetic, Block Design and Picture Arrangement.

Initially, 112 children with ADHD were randomized over the three interventions: neurofeedback (NF; $n = 39$), methylphenidate (MPH; $n = 36$) and physical activity (PA; $n = 37$). Hundred and three children completed the study. Nine children dropped out due to motivational ($n = 1$) or practical reasons ($n = 6$) or

medical contraindications ($n = 2$). The dropout rate did not differ for NF [$n = 1(2.6\%)$], MPH [$n = 5(13.9\%)$] and PA [$n = 3(8.1\%)$], $p = .164$. The consort flow diagram is presented in Figure 1.

EEG power spectra measures during EO, EC and task (effortful) conditions were available for 81 children at pre- and postintervention ($n = 29$ NF, $n = 25$ MPH, $n = 27$ PA). Missing data were due to technical reasons ($n = 5$), data quality at T0/T1 ($n = 10$), extremely poor task performance on more than four out of six runs of the SST at T0/T1 ($n = 6$) or motivational problems ($n = 1$).

Trial design

A multicentre three-way parallel group study with balanced randomization was conducted. Randomization was established using a computerized random number generator (Dallal, 2007). Stocks of nine unmarked sealed envelopes were presented to parents at intake by the lead investigators. Parents randomly picked an envelope revealing treatment allocation.

The current study aimed to enroll 186 participants. In total, 135 children with ADHD were assessed for eligibility and eventually 112 participants were randomized over the three intervention conditions. For three groups, a total sample size of 66 (i.e. 22 per group) was calculated (by G*power version 3.1.5 (Faul, Erdefelder, Lang, & Bunchner, 2007) to be sufficient to detect a medium effect size ($f = .25$) in a repeated measure (RM) analysis of variance (ANOVA) with an alpha of 0.05 and a power of 95%. In case of two groups, a total sample size of 54

(i.e. 27 per group) was calculated to detect a medium effect size ($f = .25$) in a RM ANOVA with an alpha of 0.05 and a power of 95%. A medium effect size difference between treatments was considered clinically relevant to detect. Because in total 112 participants were randomized over the three groups instead of 186 participants; the current study did not achieve the statistical power needed to detect smaller effect sizes than medium ($f < .25$) between groups. This trial is registered in the US trial register (Ref. No. NCT01363544) and the current analyses were planned as secondary outcome measures.

Interventions

NF and PA treatment comprised three individual training sessions a week, over a period of around 10 weeks. One training session lasted 45 min, with 20 min of effective training.

Neurofeedback. Theta/beta training was applied unidirectionally, with the aim to inhibit theta (4–8 Hz) and reinforce beta (13–20 Hz) activity at Cz. The THERAPRAX[®] EEG Biofeedback system (Neuroconn GmbH, Ilmenau, Germany) with a DC-amplifier and a sampling rate of 128 Hz was used to transmit and analyse the EEG signal. Reference and ground electrodes were attached to right and left mastoids respectively. Electro-oculogram (EOG) was obtained with two electrodes at external canthi, and two electrodes at infra- and supraorbital sides. Ocular correction was applied as described in Schlegelmilch, Markert, Berkes, and Schellhorn (2004).




Figure 1 Flow diagram of RCT

Subsequently, theta/beta index [$\text{theta}(\mu\text{V}^2/\text{Hz}) - \text{beta}(\mu\text{V}^2/\text{Hz}) / \text{theta}(\mu\text{V}^2/\text{Hz}) + \text{beta}(\mu\text{V}^2/\text{Hz})$] was computed with a short-time-Fourier transformed moving average for direct feedback.

The mean number of training sessions of participants who completed the assessments at postintervention ($n = 38$) was 29 ($M = 28.53$, $SD = 2.63$, range between 19 and 30). Each training session started with a 1-min baseline theta/beta index measurement, followed by 10 runs of NF. Each run comprised four 30-s epochs. Theta/beta index was represented to the participant by simple graphics on a screen. Successful reduction of the theta/beta index as averaged over one epoch relative to the baseline was rewarded with the appearance of a sun and granted with credits. The first run of the first training started on a training level with the aim to reduce the theta/beta index with 3%. The training level increased or decreased based on performance of former runs and could range between 3% and 52%, relative to training session baseline, over the total treatment period of 10 weeks. Higher training levels were rewarded with more credits.

Transfer trials without immediate visual feedback were included from session 11 (25%) and session 21 (50%) onwards. During transfer trials, patients received feedback on their performance after the trial was completed and did not receive feedback during the trial. To further transfer learned behaviours, participants were instructed to retrieve their NF experiences by watching printed graphics of the training during school and homework. Compliance was verified by questioning the participants whether they used the transfer cards over the intervention period. Transfer cards were used by 84% of the participants.

Medication. A 4-week double-blind randomized placebo-controlled titration was used to determine the optimal individual dose of short-acting MPH. The titration was preceded by a baseline week to determine ADHD symptoms without MPH, followed by a lead-in week in which on three consecutive days, twice-daily (at breakfast and lunch time) doses of 5 mg, 10 mg, and 15 mg (<25 kg body weight) or 20 mg (>25 kg body weight) MPH were used to assess adverse effects. During the titration phase, children received in a pseudo-random order each of the three doses of MPH or placebo for 1 week, twice daily. At the end of each week, parents and teacher were asked to evaluate inattention and hyperactivity/impulsivity symptoms on the DBDRS and adverse effects on the MTA Side Effect Rating Scale (Greenhill et al., 1996). A standardized procedure (Greenhill, Halperin, & Abikoff, 1999) was used to classify children as responder ($n = 29$) or nonresponder ($n = 2$). Both nonresponders were treated with 5 mg MPH twice daily during the intervention period. The child's psychiatrist prescribed the twice-daily optimal dose for the remaining intervention period for responders [5 mg to 10 (eight responders and two nonresponders), 10 mg to 14, 15 mg to two and 20 mg to five children].

Physical activity. Maximum heart rate (HR_{max}) was determined before the start of the first training session. The mean number of completed training sessions was 27 (27.74 ± 3.56) with a minimum of 12 sessions. Each training session started with 5-min of warming up followed by five 2-min exercises at a level of 70–80% of HR_{max} . After a 5-min break, five 2-min exercises of 80–100% of HR_{max} were performed. The training finished with a 5 min cool down. Time and heart rate were monitored and registered using POLAR (model FTM4).

Behavioural assessment

Behavioural outcome measures included parent and teacher reports on the Strengths and Weaknesses of ADHD symptoms and Normal behaviour scale (SWAN; Swanson, Schuck, Mann, & Carlson, 2006).

Physiological measures

EEG recording started with 3 min EO and 3 min EC resting conditions, followed by a task condition using the SST. The SST has been extensively described in Janssen et al. (2015).

Electrophysiological recordings

Continuous EEG was recorded at 512 Hz using the ActiveTwo Biosemi system and ActiView software (Biosemi, Amsterdam, The Netherlands) from 128 scalp electrodes according to the ABC labelling system, referenced to the active common mode and grounded to the passive driven right leg, which functions as a feedback loop to drive average potentials across electrodes to the amplifier zero. The EOG was obtained using two electrodes at the external canthi, and two electrodes at infra- and supraorbital sides. Reference electrodes were placed at both mastoids.

Off-line analysis was performed with Brain Vision Analyzer 2 software (Brain Products, Gilching, Germany). The sampling rate was down-sampled to 256 Hz and scalp electrodes were rereferenced to the average of the mastoids. Data were band-pass filtered at 0.1–30 Hz at 24 dB/oct and a 50-Hz notch filter was applied. Ocular artefacts were corrected with the method of Gratton & Coles (Gratton, Coles, & Donchin, 1983). The continuous EEG was segmented in 2-s intervals and automatic artefact rejection was applied to segments with amplitudes exceeding $\pm 100 \mu\text{V}$. At least 30 artefact-free segments were required for EC, EO and task conditions for further analysis. The remaining segments were fast Fourier transformed and averaged. Mean power was calculated for theta (4–8 Hz), alpha (8–12 Hz) and beta (13–20 Hz) frequency bands at midline electrodes (Fz, Cz, Pz).

Procedure

The study was approved by the national medical ethics committee, the central committee on research involving human subjects (NL 31641.029.10 CCMO). Written informed consent was obtained before participation from parents and children aged 11 years or older. Children were recruited through mental health outpatient facilities in the West of the Netherlands.

Pre- and postintervention measures included behavioural questionnaires, neuropsychological tasks and EEG. Preintervention assessment took place in the week prior to the start of the intervention. Postintervention assessment took place approximately 1 week after the last training. The MPH group continued use of medication up to postintervention. Interventions took place between September 2010 and March 2014.

Statistics

Statistical analyses were performed with SPSS 20 (IBM Corp, 2011). Significance was assumed if $p < .05$ (two-tailed). Demographic data were compared between groups with one-way ANOVA or χ^2 test with Fisher exact correction. Significant group effects were further explored with pairwise group comparisons to locate group differences. Attrition analysis was performed with ANOVA by comparing the total sample with the EEG subsample on group characteristics, and by exploring possible interactions with treatment group.

Power spectra measures were \log_{10} -transformed to obtain normally distributed data. Separate general linear model (GLM) ANCOVAs were used for each condition (EC, EO, task) and frequency band (theta, alpha, beta) with time [pre-intervention (T0), and post-intervention (T1)] and location (Fz, Cz, Pz) as within-subject factors and treatment group as between-subject factor. Since it is known that EEG power

spectra change during maturation (Clarke, Barry, McCarthy, & Selikowitz, 2001), age was inserted as covariate in all analyses. Significant interactions involving group were further explored with separate post hoc GLM ANCOVAs for each pair of treatments. EEG effects were evaluated using multivariate test criteria, because multivariate results are more robust in case of violations of sphericity (Vasey & Thayer, 1987). Only time effects, group main effects and interactions with group are reported (see Table S1 available online for location effects). For the main outcomes, mean difference and 95% confidence interval [95% CI] are reported. Effect sizes are reported as partial eta-squared (η_p^2), with effects interpreted as small (.01), medium (.06) or large (.14).

Pearson correlations were calculated in the total sample between baseline EEG power measures and both SWAN scales and performance measures on the SST, covarying for age, in order to obtain functional correlates of the frequency bands of interest. The predictive power of baseline power spectra and power spectra changes from pre- to postintervention in relation to changes in ADHD symptoms were explored with multiple linear regression. Only frequency bands and conditions that were significantly different between treatment groups from pre- to postintervention were considered. Separate backward regressions were performed for the NF and MPH groups. Dependent variables were teacher- and parent-rated SWAN Inattention and Hyperactivity/Impulsivity scores, and predictors were age, baseline power and change in power, with $p > .10$ as removal criterion. Additionally, the same analyses were performed exploratory with the dependent variables stop-signal reaction time (SSRT) as measure of response inhibition speed, mean reaction time (MRT) on go trials as measure of processing speed and commission and omission errors during go trials on the SST as measures of accuracy.

Results

Group characteristics

At T0, there were no differences between the treatment groups in age, IQ, gender, ADHD subtype and symptom severity (see Table 1). Furthermore, groups did not differ in baseline measures of theta power (all $p > .10$). However, there were some baseline differences between groups in beta and alpha power

during the EO and task conditions at Cz and Pz electrodes ($p < .05$). Post-hoc tests showed less beta power in the PA group than the NF and MPH groups. During the task condition, the PA group demonstrated less alpha power at Fz than the MPH group ($p = .010$).

Number of artefact-free segments at T0 did not differ between groups for EC ($M = 79$), EO ($M = 84$) and task condition ($M = 580$) (all $p > .10$). At T1, groups did not differ on number of segments for EO ($M = 86$); however, the medication group had more segments than the PA group for the EC (NF = 79, MPH = 85, PA = 74), $F(1,50) = 7.66$, $p = .008$ and task condition (NF = 620, MPH = 665, PA = 526), $F(1,50) = 7.77$, $p = .008$.

Attrition analysis

There were no differences in group characteristics between the EEG subgroup and the total randomized group, nor were there any interactions with treatment group.

EEG results

ANCOVA results for each condition and frequency band are shown in Table 2. Log-transformed EEG power spectra of theta, alpha and beta frequency bands at pre- (T0) and post- (T1) intervention are shown in Figure 2. Figure 3 shows the 95% CI of treatment-related changes for the significant Time \times Group interactions.

Main findings were Time \times Group interactions for the theta band during EO and task conditions and for the alpha band during the task condition. Post-hoc tests for the EO condition revealed that both NF and MPH showed greater reductions in theta power than PA from pre- to postmeasurement, $F(1,53) = 4.48$, $p = .039$, $\eta_p^2 = .08$, mean

Table 1 Group characteristics at preintervention (T0)

	NF ($n = 29$)		MPH ($n = 25$)		PA ($n = 27$)		Between-group difference	
	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>	<i>F</i> (2,78)	<i>p</i>
Demographic data								
Age (years)	10.02	1.77	9.09	1.10	9.79	1.92	2.29	ns
IQ	99.28	12.58	100.28	14.69	98.00	12.47	0.20	ns
Gender (M/F)	21/8		19/6		21/6		0.28 ^a	ns
ADHD subtype (C/I/HI)	21/7/1		16/9/0		20/7/0		2.76 ^b	ns
DBDRS parents								
Inattention	15.79	4.81	16.40	5.91	16.30	5.10	0.11	ns
Hyperactivity/Impulsivity	13.93	5.66	12.76	5.80	13.07	6.17	0.29	ns
DBDRS teacher								
Inattention	15.17	5.46	16.72	6.54	16.00	4.91	0.51	ns
Hyperactivity/Impulsivity	14.10	7.26	11.72	9.61	13.19	7.36	0.59	ns

NF, neurofeedback; MPH, methylphenidate; PA, physical activity; DBDRS, Disruptive Behaviour Disorders Rating Scale; C, ADHD combined type; I, ADHD inattentive type; HI, ADHD hyperactive/impulsive type.

^a $\chi^2(2)$.

^b $\chi^2(4)$.

Table 2 GLM ANCOVA analyses of pre- and postintervention power spectra for three conditions

		T		T × G		T × L		T × G × L		Post-hoc tests	
		F(1,78)	η_p^2	F(2,78)	η_p^2	F(2,76)	η_p^2	F(4,154)	η_p^2		
EC	Theta	0.09	.00	2.14	.05	0.34	.01	1.27	.03	(NF = MPH) > PA	
	Alpha	0.02	.00	0.96	.03	0.26	.01	0.41	.01		
	Beta	1.73	.02	0.63	.02	0.90	.02	0.33	.00		
EO	Theta	0.00	.00	3.71*	.09	0.11	.00	1.34	.03		
	Alpha	1.17	.02	2.87	.07	0.11	.00	1.20	.03		
	Beta	0.63	.01	1.77	.04	0.45	.01	0.74	.02		
Task	Theta	0.02	.00	3.62*	.09	0.48	.01	0.89	.02		MPH > PA, NF = PA, NF = MPH
	Alpha	0.03	.00	4.01*	.09	0.24	.01	0.82	.02		
	Beta	1.72	.02	1.80	.05	0.47	.01	0.49	.01		

EC, eyes closed, EO, eyes open; NF, neurofeedback; MPH, methylphenidate; PA, physical activity; T, time; G, group; C, condition; L, location.

* $p < .05$.




Figure 2 EEG power spectra at pre (T0)- and post (T1) intervention for the average of midline electrodes Fz, Cz and Pz. Note. Estimated marginal means are log-transformed absolute power (μV^2) with 95% confidence intervals, adjusted for covariate age at 9.66 years. During the eyes open condition, both the neurofeedback and methylphenidate groups showed greater reductions in theta power than the physical activity group. During the task condition, only the methylphenidate group showed greater reductions in theta and alpha power than the physical activity group




Figure 3 EEG power changes between pre- and postintervention (T1–T0). Note. Estimated marginal means are log-transformed absolute power (μV^2) differences from pre (T0)- to post (T1)intervention, with 95% confidence intervals. During the eyes open condition, both the neurofeedback (NF) and methylphenidate (MPH) groups showed greater reductions in theta power than the physical activity (PA) group. During the task condition, only the MPH group showed greater reductions in theta and alpha power than the PA group

difference_(NF-PA) = -0.073 , 95%CI = $[-0.142, -0.004]$, and $F(1,49) = 6.96$, $p = .011$, $\eta_p^2 = .12$, mean difference_(MPH-PA) = -0.092 , 95%CI = $[-0.162, -0.022]$ respectively, with medium/large effect sizes. NF and MPH showed comparable decreases in theta, $F(1,51) = 0.16$, $p = .691$, $\eta_p^2 = .00$, mean difference_(NF-MPH) = -0.012 , 95%CI = $[-0.074, 0.050]$.

Post-hoc tests for the task condition showed a larger decrease in theta power for MPH compared to PA, $F(1,49) = 5.35$, $p = .025$, mean difference_(MPH-PA) = -0.092 , 95%CI = $[-0.173, -0.012]$, with a medium/large effect size, $\eta_p^2 = .10$. No effects were found for NF compared to PA, $F(1,53) = 2.52$, $p = .120$, $\eta_p^2 = .05$, mean difference_(NF-PA) = -0.053 , 95%CI = $[-0.120, 0.014]$ or NF compared to MPH, $F(1,51) = 1.00$, $p = .322$, $\eta_p^2 = .02$, mean difference_(NF-MPH) = 0.027 , 95%CI = $[-0.027, 0.080]$. For the alpha band, the MPH group showed a greater reduction in power compared to the PA group, $F(1,49) = 6.68$, $p = .013$, $\eta_p^2 = .12$, mean difference_(MPH-PA) = -0.104 , 95%CI = $[-0.184, -0.023]$. Again, no effects were found for NF compared to PA, $F(1,53) = 2.17$, $p = .147$, $\eta_p^2 = .04$, mean difference_(NF-PA) = -0.053 , 95%CI = $[-0.125, 0.019]$ or NF compared to MPH, $F(1,51) = 1.79$, $p = .187$, $\eta_p^2 = .03$, mean difference_(NF-MPH) = 0.041 , 95%CI = $[-0.020, 0.102]$.

Relations between EEG, behaviour and cognition

Since electrode location proved to be irrelevant for the results of this study, correlational and regression analyses were only performed for the Cz electrode to limit the number of tests.

Preintervention. Moderate sized correlations were found between theta power at T0 and teacher-rated inattention and hyperactivity/impulsivity for EO, EC and task conditions (correlations between $r(80) = .33$, $p < .01$ and $r(80) = .39$, $p < .001$), indicating that children with greater theta power display greater ADHD symptom severity. No other significant corre-

lations were found, except a weak correlation between alpha power during the EO condition and the parent-reported inattention, $r(80) = -.22$, $p = .048$. Furthermore, alpha power at T0 correlated weakly with number of commission errors, $r(77) = .274$, $p = .015$, and a trend was found with SSRT, $r(77) = .219$, $p = .052$, on the task condition (SST).

Intervention effects. For the EO condition, reductions in theta power from pre- to postintervention were predictive of reductions in parent-rated inattention symptoms, only for the NF group, $R^2 = .24$, $F(1,27) = 8.60$, $p = .007$. Furthermore, baseline theta power and reductions in theta power over time were predictive of parent-rated reductions in hyperactivity/impulsivity symptoms in the NF group, $\beta = .60$, $t(26) = 2.51$, $p = .019$, and $\beta = .81$, $t(26) = 3.37$, $p = .002$, respectively. The overall model fit was $R^2 = .30$, $F(2,26) = 5.68$, $p = .009$. During the task condition, lower alpha power at baseline was predictive for greater reductions in teacher-rated hyperactivity/impulsivity in the medication group, $R^2 = .20$, $F(1,23) = 5.67$, $p = .026$. No effects were found for the cognitive measures.

Discussion

The efficacy of NF as treatment for children with ADHD is still debated and direct comparisons between NF and stimulant medication have produced inconsistent results. An important part of this debate revolves around whether NF induces specific treatment effects that are related to alterations in brain function. This RCT examined EEG power spectra before and after NF, stimulant medication and PA – as semiactive treatment group – to determine whether NF can induce sustained alterations in brain function, and how results compare to effects of stimulant medication. Both NF and medication treatment resulted in reductions in theta power from pre- to postintervention during the EO resting condition, compared to the PA group. During the effortful (task) condition, only the medication group

showed reductions in theta and alpha power compared to the PA group.

Our results are similar to Gevensleben et al. (2009) in respect to three main findings: (a) NF induced a reduction in theta power during an EO resting condition compared to an active control group, (b) higher baseline theta power at preintervention was predictive of greater ADHD symptom reduction from pre- to postintervention and (c) greater changes in theta power from pre- to postintervention were predictive of greater ADHD symptom reductions. However, the study of Gevensleben et al. (2009) found this theta reduction only for the combined effects of theta/beta (18 sessions) and SCP training (18 sessions) blocks, but not for any of the training blocks separately. Although this could mean that changes in theta power are not protocol-specific, another explanation, as suggested by the authors, is the relatively small number of sessions per training block, which might not be enough to reveal protocol specific effects. Protocol specific decreases in theta were found by the study of Bink, van Nieuwenhuizen, Popma, Bongers, and van Boxtel (2015), who showed that over the course of theta/SMR NF training youngster became better able in suppressing theta activity within training sessions. In contrast to the findings of this study, Gevensleben et al. (2009) and Bink et al. (2015), the study by Ogrim et al. (2013) did not find evidence for changes in theta power in EO resting and task conditions. This may be attributable to the individualized NF protocols – only half of the children received theta/beta training ($n = 7$) – that could have produced more heterogeneous EEG responses or the relatively small sample size.

Although the NF group showed a specific reduction in theta power during the EO resting condition, no such effects were found during EC and task (effortful) conditions. Especially the lack of any effects during the task condition may be surprising, as children had to produce an active attentive state during the NF sessions, while during the EO condition children had to remain relaxed and inactive. Hence, one would expect NF effects to transfer to the task condition rather than the EO resting condition. It may be speculated that theta/beta NF produces sustained alterations in brain function that are indeed related to an activated attentional state during rest, but still in a ‘passive’ context as far that there is no goal-directed task to perform during NF. This could explain why the EEG alterations did not generalize to the goal-directed task condition in our study. Furthermore, this interpretation is consistent with the meta-study by Sonuga-Barke et al. (2013) on the effectiveness of NF in which no evidence was found for probably blinded informants that were mostly teachers. Teachers observe a child mainly during goal-directed and task-related activities. Behavioural and neurophysiological effects of NF may not generalize to this particular context. Our

finding that changes in theta were specifically predictive of parent-informed ADHD symptom reductions, but not for the teacher reports, further supports our interpretation.

Another notable observation is that beta power did not change between pre- and postintervention for the NF group, as opposed to theta power. Other studies also failed to demonstrate treatment effects in the beta power band (Bink et al., 2015; Gevensleben et al., 2009; Kropotov et al., 2007). This may be explained by several factors. First, increased theta power seems to be a more robust marker of ADHD than decreased beta power (Loo & Barkley, 2005). This seems to be true for the current study as well, as we found highly significant correlations between teacher-reported ADHD symptoms and theta power, but not for beta power. The theta band, therefore, may be more sensitive to change in ADHD symptoms. Second, theta power may be more reliably measured with EEG than beta power. Conventional EEG frequency bands overlap with the frequency spectrum of electromyographic (EMG) activity produced by skeletal muscles (Goncharova, McFarland, Vaughan, & Wolpaw, 2003; McMenamin, Shackman, Greischar, & Davidson, 2011). Although the peak frequency of EMG is at relatively high frequencies, the spectrum of EMG is very broad and may influence adjacent beta frequencies more than lower frequency bands such as theta. Despite specific instructions during neurofeedback training to prevent excessive muscular tension, it cannot be ruled out that some children used more subtle covert muscular tension to influence the theta/beta ratio. Third, in this study we used a theta/beta index as feedback signal that was biased to represent theta more than beta. This bias was implemented by correcting theta and beta bands for their bandwidth. An advantage of this index calculation is that extreme theta/beta values, which may result from muscular artefacts, have less disruptive effects on the training. However, our method of index calculation may have reduced training effects in the beta band.

The medication group showed similar reductions in theta power from pre- to postintervention as obtained in the NF group; however, for the medication group this effect was also demonstrated for the task condition. Reductions in theta power with MPH have been found in other, but uncontrolled studies, focusing on chronic effects (6 months) during an EC resting condition (Clarke, Barry, Bond, et al., 2002; Clarke et al., 2003) or acute effects during task conditions (Song et al., 2005; Swartwood et al., 1998), while a double-blind placebo controlled study did not demonstrate theta reduction (Loo et al., 2004), although the authors speculated that large variability and low statistical power may have resulted in only a statistical trend for theta. In contrast to other studies, we found no effects in the

beta frequency band (Clarke, Barry, Bond, et al., 2002; Loo et al., 2004; Song et al., 2005).

An additional finding for children that received medication was a decrease in alpha power during the SST, which is consistent with other studies (Loo, Teale, & Reite, 1999; Swartwood et al., 1998). This finding is in contrast with Loo et al. (2004), who demonstrated increased alpha power during an EO resting condition. The alpha increase as found by Loo et al. (2004) is somewhat surprising, considering that alpha seems inversely related to arousal: lower alpha power has been associated with higher cortical function (Gevins et al., 1979), visual spatial attention (Vázquez Marrufo, Vaquero, Cardoso, & Gómez, 2001), increased BOLD response in fMRI (Herrmann & Debener, 2008) and increased SCL (Barry, Clarke, Johnstone, McCarthy, & Selikowitz, 2009). The association between alpha and cognition may be positive as well, according to the neural efficiency hypothesis, where alpha amplitude reflects inhibition of nonessential activity, which may in turn facilitate task performance (Bazanov & Vernon, 2013). However, in our study, lower alpha power was related to better task performance at baseline, although we could not demonstrate a relation between change in alpha power and performance improvement.

Taken together, our RCT results replicate previous uncontrolled MPH studies concerning theta reduction; however, additional RCTs are required to demonstrate the robustness of the findings and to address the contradicting findings in the alpha frequency band.

Theta/beta has originally been interpreted as a marker for central nervous system (CNS) arousal; however, this proposition is increasingly challenged. Studies have failed to find a relation between theta/beta and skin conductance level (SCL), which is considered as the gold-standard index of arousal. By contrast, alpha power shows a negative relation with SCL (Barry et al., 2005; Barry, Clarke, Johnstone, Brown, et al., 2009). Barry et al. (2009) suggests that elevated theta/beta in ADHD may not reflect an arousal deficit, but rather an activation or processing deficit, as theta/beta is related to task performance. However, this hypothesis remains to be further explored, as it does not readily explain elevated theta/beta in ADHD during resting conditions. Our findings of a relation between alpha power and task performance at baseline, but no evidence for a relation between theta power and task performance, further contradict this hypothesis. The conceptual shift away from arousal does consequently challenge the interpretation of our treatment findings and studies into the functional significance of theta and alpha power are especially needed to improve our understanding of electrophysiological treatment effects.

Some limitations of this study should be mentioned. Although treatment groups were comparable

in age, IQ, gender and ADHD severity, the findings for the alpha band should be interpreted more cautiously because of baseline differences between the medication and PA group. Baseline differences were also apparent for the beta band; however, considering the lack of any time or interaction effects with treatment group, or relation with ADHD symptomatology, it is unlikely to have confounded the results. Another limitation is that the current study lacks power to detect small effect sizes, which may be of interest to learn more about neural treatment mechanisms. The nonsignificant difference during the task condition between the NF and semiactive control condition, and between NF and MPH, may have reached significance with larger sample sizes.

Conclusion

In conclusion, we found evidence for specific neurophysiological effects after theta/beta neurofeedback and stimulant treatment in children with ADHD. However, for NF these effects did not generalize to an active task-related and goal-directed condition, potentially explaining reduced behavioural effects of NF in the classroom as reported by teachers (Sonuga-Barke et al., 2013). These findings are in concordance with the behavioural (Geladé et al., in press) and event-related potential (Janssen et al., in press) results of the current study as well, which showed small behavioural improvements over time as reported by parents (although not more than the semi-active control group), but no changes according to the teacher. Additionally, at postintervention, ERP effects during the task condition were found only for children that received stimulant medication. Considering the fact that effects of NF were confined to the theta band during rest, and that children with increased theta showed larger improvements, NF protocols may benefit from training solely theta activity during both task and nontask conditions in children with elevated theta.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Table S1. GLM ANCOVA analyses of pre- and post-intervention power spectra for three conditions

Acknowledgements

This trial is funded by the Netherlands Organization for Health Research and Development (ZonMw): 157 003 012. ZonMw funded the trial, but had no role in the data analysis, manuscript preparation or decision to publish. The authors have declared that they have no conflicts of interest in relation to this study.

The authors like to thank all participating children and families for their contribution, as well as all research interns for their valuable support. Furthermore, they would like to thank the participating centres

of child and adolescent psychiatry: Yulius Academie, Groene Hart ziekenhuis, Lucertis, Alles Kits, GGZ Delfland, Maasstad ziekenhuis, RIAGG Schiedam, Kinderpraktijk Zoetermeer, Albert Schweitzer ziekenhuis, Groos Mentaal Beter Jong, ADHD behandelcentrum, GGZ inGeest and PuntP.

Correspondence

Tieme Willem Pieter Janssen, Department of Clinical Neuropsychology, VU University Amsterdam, Van der Boechorststraat 1, 1081BT, Amsterdam, The Netherlands; Email: twp.janssen@vu.nl

Key points

- The efficacy of NF as treatment for ADHD, and in comparison to pharmacological intervention, is still a highly debated subject.
- Contributing to this discussion is the lack of a mechanistic explanation of how NF may ameliorate symptoms of ADHD.
- This study provides evidence for specific neurophysiological effects after theta/beta NF and medication treatment in children with ADHD.
- For NF, these effects did not generalize to an active task condition, potentially explaining reduced behavioural effects in the classroom.
- These results may have important implications for the development of future NF protocols.

References

- Alderson, R., Rapport, M., & Kofler, M. (2007). Attention-deficit/hyperactivity disorder and behavioral inhibition: A meta-analytic review of the stop-signal paradigm. *Journal of Abnormal Child Psychology*, 35, 745–758.
- Arns, M., Conners, C.K., & Kraemer, H.C. (2013). A decade of EEG Theta/Beta Ratio Research in ADHD: A meta-analysis. *Journal of Attention Disorders*, 17, 374–383.
- Arns, M., de Ridder, S., & Strehl, U. (2009). Efficacy of Neurofeedback Treatment in ADHD: The Effects on Inattention, Impulsivity and Hyperactivity: A Meta-Analysis. *Clinical EEG and Neuroscience*, 40, 180–189.
- Arns, M., Heinrich, H., & Strehl, U. (2014). Evaluation of neurofeedback in ADHD: The long and winding road. *Biological Psychology*, 95, 108–115. Elsevier B.V.
- Arnsten, A.F.T. (2006). Stimulants: Therapeutic actions in ADHD. *Neuropsychopharmacology*, 31, 2376–2383.
- Barkley, R.A. (1997). Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. *Psychological Bulletin*, 121, 65–94.
- Barry, R.J., Clarke, A.R., Johnstone, S.J., Brown, C.R., Bruggemann, J.M., & van Rijbroek, I. (2009). Caffeine effects on resting-state arousal in children. *International Journal of Psychophysiology*, 73, 355–361. Elsevier B.V.
- Barry, R.J., Clarke, A.R., Johnstone, S.J., McCarthy, R., & Selikowitz, M. (2009). Electroencephalogram theta/beta ratio and arousal in attention-deficit/hyperactivity disorder: Evidence of independent processes. *Biological Psychiatry*, 66, 398–401. Society of Biological Psychiatry.
- Barry, R.J., Rushby, J.A., Wallace, M.J., Clarke, A.R., Johnstone, S.J., & Zlojutro, I. (2005). Caffeine effects on resting-state arousal. *Clinical Neurophysiology*, 116, 2693–2700.
- Bazanov, O.M., & Vernon, D. (2013). Interpreting EEG alpha activity. *Neuroscience and Biobehavioral Reviews*, 44, 94–110. Elsevier Ltd.
- Biederman, J. (2005 June 1). Attention-deficit/hyperactivity disorder: A selective overview. *Biological Psychiatry*, 57, 1215–1220.
- Bink, M., van Nieuwenhuizen, C., Popma, A., Bongers, I.L., & van Boxtel, G.J.M. (2015). Behavioral effects of neurofeedback in adolescents with ADHD: A randomized controlled trial. *European Child & Adolescent Psychiatry*, 24, 1035–1048. Springer Berlin Heidelberg.
- Clarke, A.R., Barry, R.J., Bond, D., McCarthy, R., & Selikowitz, M. (2002). Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl)*, 164, 277–284.
- Clarke, A.R., Barry, R.J., McCarthy, R., & Selikowitz, M. (2001). Age and sex effects in the EEG: Development of the normal child. *Clinical Neurophysiology*, 112, 806–814.
- Clarke, A.R., Barry, R.J., McCarthy, R., & Selikowitz, M. (2002). EEG differences between good and poor responders to methylphenidate and dexamphetamine in children with attention-deficit/hyperactivity disorder. *Clinical Neurophysiology*, 113, 194–205.
- Clarke, A.R., Barry, R.J., McCarthy, R., Selikowitz, M., Brown, C.R., & Croft, R.J. (2003). Effects of stimulant medications on the EEG of children with Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive type. *International Journal of Psychophysiology*, 47, 129–137.
- Coghill, D., Soutullo, C., d'Aubuisson, C., Preuss, U., Lindback, T., Silverberg, M., & Buitelaar, J. (2008). Impact of attention-deficit/hyperactivity disorder on the patient and family: Results from a European survey. *Child and Adolescent Psychiatry and Mental Health*, 2, 31.
- Dallal, G.E. (2007). Randomization plan generator; first generator. Available from: <http://www.randomization.com> [last accessed February 2010].
- Duric, N.S., Assmus, J., Gundersen, D., & Elgen, I.B. (2012 January). Neurofeedback for the treatment of children and adolescents with ADHD: A randomized and controlled clinical trial using parental reports. *BMC Psychiatry*, 12, 1–8.
- Faraone, S.V., & Buitelaar, J. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. *European Child & Adolescent Psychiatry*, 19, 353–364.
- Faul, F., Erdfelder, E., Lang, A.G., & Bunchner, A. (2007). G*power 3: A flexible statistical power analysis program for the social, behavioral and biomedical sciences. *Behavior Research Methods*, 39, 175–191.
- Geladé, K., Janssen, T.W.P., Bink, M., van Mourik, R., Maras, A., & Oosterlaan, J. (in press). An RCT into the behavioural effects of neurofeedback compared to methylphenidate and

- physical activity in children with ADHD. *Journal of Clinical Psychiatry*.
- Gevensleben, H., Holl, B., Albrecht, B., Schlamp, D., Kratz, O., Studer, P., ... & Heinrich, H. (2009). Distinct EEG effects related to neurofeedback training in children with ADHD: A randomized controlled trial. *International Journal of Psychophysiology*, *74*, 149–157.
- Gevensleben, H., Rothenberger, A., Moll, G.H., & Heinrich, H. (2012). Neurofeedback in children with ADHD: Validation and challenges. *Expert Review of Neurotherapeutics*, *12*, 447–460.
- Gevins, A.S., Zeitlin, G.M., Doyle, J.C., Yingling, C.D., Schaffer, R.E., Callaway, E., & Yeager, C.L. (1979). Electroencephalogram correlates of higher cortical functions. *Science*, *203*, 665–668.
- Goncharova, I., McFarland, D., Vaughan, T., & Wolpaw, J. (2003). EMG contamination of EEG: Spectral and topographical characteristics. *Clinical Neurophysiology*, *114*, 1580–1593.
- Graham, J., & Coghill, D. (2008). Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: Epidemiology, prevention and management. *CNS Drugs*, *22*, 213–237.
- Gratton, G., Coles, M., & Donchin, E. (1983). A new method for off-line removal of ocular artifact. *Electroencephalography and Clinical Neurophysiology*, *55*, 468–484.
- Greenhill, L.L., Abikoff, H.B., Arnold, L.E., Cantwell, D.P., Conners, K., Elliott, G., ... & Wells, K. (1996). Medication treatment strategies in the MTA study: Relevance to clinicians and researchers. *Journal of American Academy of Child and Adolescent Psychiatry*, *34*, 1304–1313.
- Greenhill, L.L., Halperin, J.M., & Abikoff, H. (1999). Stimulant medications. *Journal of American Academy of Child and Adolescent Psychiatry*, *38*, 503–512.
- Halperin, J.M., Berwid, O.G., & O'Neill, S. (2014). Healthy body, healthy mind?: The effectiveness of physical activity to treat ADHD in children. *Child and Adolescent Psychiatric Clinics of North America*, *23*, 899–936.
- Herrmann, C.S., & Debener, S. (2008). Simultaneous recording of EEG and BOLD responses: A historical perspective. *International Journal of Psychophysiology*, *67*, 161–168.
- IBM Corp. (2011). *IBM SPSS statistics for Windows*. Armonk, NY: IBM Corp.
- Janssen, T.W.P., Bink, M., Gelade, K., Mourik, R., Maras, A., & Oosterlaan, J. (in press). A randomized controlled trial into the effects of neurofeedback, methylphenidate and physical activity on event-related potentials in children with attention-deficit/hyperactivity disorder. *Journal of Child and Adolescent Psychopharmacology*.
- Janssen, T.W.P., Heslenfeld, D.J., van Mourik, R., Gelade, K., Maras, A., & Oosterlaan, J. (2015). Alterations in the ventral attention network during the stop-signal task in children With ADHD: An event-related potential source imaging study. *Journal of Attention Disorders*. Advanced online publication. doi:10.1177/1087054715580847.
- Kropotov, J.D., Grin-Yatsenko, V.A., Ponomarev, V.A., Chutko, L.S., Yakovenko, E.A., & Nikishena, I.S. (2007). Changes in EEG spectrograms, event-related potentials and event-related desynchronization induced by relative beta training in ADHD children. *Journal of Neurotherapy*, *11*, 3–11.
- Lijffijt, M., Kenemans, J.L., Verbaten, M.N., & van Engeland, H. (2005). A meta-analytic review of stopping performance in attention-deficit/hyperactivity disorder: Deficient inhibitory motor control? *Journal of Abnormal Psychology*, *114*, 216–222.
- Logan, G., & Cowan, W. (1984). On the ability to inhibit simple and choice reaction time responses: A theory of an act of control. *Psychological Review*, *91*, 295–327.
- Loo, S.K., & Barkley, R.A. (2005). Clinical utility of EEG in attention deficit hyperactivity disorder. *Applied Neuropsychology*, *12*, 64–76.
- Loo, S.K., Cho, A., Hale, T.S., McGough, J., McCracken, J., & Smalley, S.L. (2013). Characterization of the theta to beta ratio in ADHD: Identifying potential sources of heterogeneity. *Journal of Attention Disorders*, *17*, 384–392.
- Loo, S.K., Hopfer, C., Teale, P.D., & Reite, M.L. (2004). EEG correlates of methylphenidate response in ADHD: Association with cognitive and behavioral measures. *Journal of Clinical Neurophysiology*, *21*, 457–464.
- Loo, S.K., & Makeig, S. (2012). Clinical utility of EEG in attention-deficit/hyperactivity disorder: A research update. *Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics*, *9*, 569–587.
- Loo, S.K., Teale, P., & Reite, M. (1999). EEG correlates of psychostimulant effects among children with ADHD: A preliminary report. *Biological Psychiatry*, *45*, 1657–1660.
- Lubar, J.F. (1991). Discourse on the development of EEG diagnostics and biofeedback for attention-deficit/hyperactivity disorders. *Biofeedback and Self-Regulation*, *16*, 201–225.
- McMenamin, B.W., Shackman, A.J., Greischar, L.L., & Davidson, R.J. (2011). Electromyogenic artifacts and electroencephalographic inferences revisited. *NeuroImage*, *54*, 4–9. Elsevier Inc.
- Meisel, V., Servera, M., Garcia-Banda, G., Cardo, E., & Moreno, I. (2013). Neurofeedback and standard pharmacological intervention in ADHD: A randomized controlled trial with six-month follow-up. *Biological Psychology*, *94*, 12–21. Elsevier B.V.
- Monastra, V.J., Monastra, D.M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. *Applied Psychophysiology and Biofeedback*, *27*, 231–249.
- Ogrim, G., & Hestad, K.A. (2013). Effects of neurofeedback versus stimulant medication in attention-deficit/hyperactivity disorder: A randomized pilot study. *Journal of Child and Adolescent Psychopharmacology*, *23*, 448–457.
- Ogrim, G., Kropotov, J., Brunner, J.F., Candrian, G., Sandvik, L., & Hestad, K.A. (2014). Predicting the clinical outcome of stimulant medication in pediatric attention-deficit/hyperactivity disorder: Data from quantitative electroencephalography, event-related potentials, and a go/no-go test. *Neuropsychiatric Disease and Treatment*, *10*, 231–242.
- Pelham, W.E., Gnagy, E.M., Greenslade, K.E., & Milich, R. (1992). Teacher ratings of DSM-III-R symptoms for the disruptive behavior disorders. *Journal of American Academy of Child and Adolescent Psychiatry*, *31*, 210–218.
- Rommel, A.-S., Halperin, J.M., Mill, J., Asherson, P., & Kuntsi, J. (2013). Protection from genetic diathesis in attention-deficit/hyperactivity disorder: Possible complementary roles of exercise. *Journal of the American Academy of Child and Adolescent Psychiatry*, *52*, 900–910. Elsevier Inc.
- Schlegelmilch, F., Markert, S., Berkes, S., & Schellhorn, K. (2004). Online ocular artifact removal for dc-EEG-signals: Estimation of dc-level. *Biomedizinische Technik*, *2*, 340–341.
- Sergeant, J. (2000). The cognitive-energetic model: An empirical approach to attention-deficit hyperactivity disorder. *Neuroscience and Biobehavioral Reviews*, *24*, 7–12.
- Snyder, S.M., & Hall, J.R. (2006). A meta-analysis of quantitative EEG power associated with attention-deficit hyperactivity disorder. *Journal of Clinical Neurophysiology*, *23*, 440–455.
- Snyder, S.M., Rugino, T.A., Hornig, M., & Stein, M.A. (2015). Integration of an EEG biomarker with a clinician's ADHD evaluation. *Brain and Behavior*, *5*, 1–17.
- Song, D.H., Shin, D.W., Jon, D.I., & Ha, E.H. (2005). Effects of methylphenidate on quantitative EEG of boys with

- attention-deficit hyperactivity disorder in continuous performance test. *Yonsei Medical Journal*, 46, 34–41.
- Sonuga-Barke, E.J.S., Bitsakou, P., & Thompson, M. (2010). Beyond the dual pathway model: Evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 49, 345–355. Elsevier Inc.
- Sonuga-Barke, E.J.S., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., ... & European ADHD Guidelines Group. (2013). Nonpharmacological Interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. *The American Journal of Psychiatry*, 170, 275–289.
- Spencer, T., Biederman, J., Wilens, T., Harding, M., O'Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. *Journal of the American Academy of Child and Adolescent Psychiatry*, 35, 409–432. The American Academy of Child and Adolescent Psychiatry.
- Swanson, J.M., Schuck, S., Mann, M., & Carlson, C. (2006). *Categorical and dimensional definitions and evaluations of symptoms of ADHD: The SNAP and SWAN rating scales*. Irvine: University of California. Available from: <http://www.adhd.net>.
- Swartwood, M.O., Swartwood, J.N., Lubar, J.F., Timmermann, D.L., Zimmerman, A.W., & Muenchen, R.A. (1998). Methylphenidate effects on EEG, behavior, and performance in boys with ADHD. *Pediatric Neurology*, 18, 244–250.
- Vasey, M.W., & Thayer, J.F. (1987). The continuing problem of false positives in repeated measures ANOVA in psychophysiology: A multivariate solution. *Psychophysiology*, 24, 479–486.
- Vázquez Marrufo, M., Vaquero, E., Cardoso, M.J., & Gómez, C.M. (2001). Temporal evolution of α and β bands during visual spatial attention. *Cognitive Brain Research*, 12, 315–320.
- Wechsler, D. (1991). *Weschler intelligence scale for children*, (3rd edn). San Antonio, TX: Psychological Corporation.
- Willcutt, E.G. (2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. *Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics*, 9, 490–499.
- Zentall, S., & Zentall, T. (1983). Optimal stimulation: A model of disordered activity and performance in normal and deviant children. *Psychological Bulletin*, 94, 446–471.

Accepted for publication: 19 November 2015

First published online: 8 January 2016

Copyright of Journal of Child Psychology & Psychiatry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.